20. The use of claim 18 or 19, wherein the antibody or antigen-binding portion thereof is to be administered intravenously, subcutaneously, intramuscularly or transdermally.

21. The use of any one of claims 18 to 20, wherein the medicament further comprises a second agent.

22. The use of claim 21, wherein the second agent is a different antibody or antigen-binding portion thereof.

23. The use of claim 21, wherein the second agent is an antibiotic.

24. The use of claim 23, wherein the antibiotic is vancomycin, metronidazole, or fidaxomicin.

25. A method of detecting *Clostridium difficile* (*C. difficile*) toxin A, comprising the steps of contacting a sample suspected or known to contain *C. difficile* toxin A with the antibody or antigen-binding portion thereof of any one of claims 1 to 14 and detecting binding of the antibody or antigen-binding portion thereof to *C. difficile* toxin A.

26. A method of isolating *Clostridium difficile* (*C. difficile*) toxin A from a sample, which comprises contacting a sample comprising or suspected of comprising *C. difficile* toxin A with the antibody or antigen-binding portion thereof of any one of claims 1 to 14.